These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 27033195)

  • 1. The Role of Statins in the Activation of Heme Oxygenase-1 in Cardiovascular Diseases.
    Piechota-Polanczyk A; Jozkowicz A
    Curr Drug Targets; 2017; 18(6):674-686. PubMed ID: 27033195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMG-CoA reductase inhibitors upregulate heme oxygenase-1 expression in murine RAW264.7 macrophages via ERK, p38 MAPK and protein kinase G pathways.
    Chen JC; Huang KC; Lin WW
    Cell Signal; 2006 Jan; 18(1):32-9. PubMed ID: 16214041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heme oxygenase-1 and cardiovascular disease.
    Immenschuh S; Schröder H
    Histol Histopathol; 2006 Jun; 21(6):679-85. PubMed ID: 16528678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells.
    Grosser N; Hemmerle A; Berndt G; Erdmann K; Hinkelmann U; Schürger S; Wijayanti N; Immenschuh S; Schröder H
    Free Radic Biol Med; 2004 Dec; 37(12):2064-71. PubMed ID: 15544924
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [HMG-CoA reductase inhibitors in prevention of cardiovascular diseases: new mechanisms, aspects and trials].
    Wojakowski W; Gmiński J
    Przegl Lek; 2000; 57(5):291-5. PubMed ID: 11057120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins?
    Balakumar P; Kathuria S; Taneja G; Kalra S; Mahadevan N
    J Mol Cell Cardiol; 2012 Jan; 52(1):83-92. PubMed ID: 21968328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antioxidant effects of statins.
    Stoll LL; McCormick ML; Denning GM; Weintraub NL
    Drugs Today (Barc); 2004 Dec; 40(12):975-90. PubMed ID: 15645009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence supporting primary prevention of cardiovascular diseases with statins: Gaps between updated clinical results and actual practice.
    Bruckert E; Ferrières J
    Arch Cardiovasc Dis; 2014 Mar; 107(3):188-200. PubMed ID: 24613429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simvastatin-dependent up-regulation of heme oxygenase-1 via mRNA stabilization in human endothelial cells.
    Hinkelmann U; Grosser N; Erdmann K; Schröder H; Immenschuh S
    Eur J Pharm Sci; 2010 Sep; 41(1):118-24. PubMed ID: 20594940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2,3,5,6-Tetramethylpyrazine (TMP) down-regulated arsenic-induced heme oxygenase-1 and ARS2 expression by inhibiting Nrf2, NF-κB, AP-1 and MAPK pathways in human proximal tubular cells.
    Gong X; Ivanov VN; Hei TK
    Arch Toxicol; 2016 Sep; 90(9):2187-2200. PubMed ID: 26404762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of heat shock proteins by statins.
    Forouzanfar F; Butler AE; Banach M; Barreto GE; Sahbekar A
    Pharmacol Res; 2018 Aug; 134():134-144. PubMed ID: 29935271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivo.
    Hsu M; Muchova L; Morioka I; Wong RJ; Schröder H; Stevenson DK
    Biochem Biophys Res Commun; 2006 May; 343(3):738-44. PubMed ID: 16563347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does it matter whether or not a lipid-lowering agent inhibits Rho kinase?
    Liao JK
    Curr Atheroscler Rep; 2007 Nov; 9(5):384-8. PubMed ID: 18001621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection.
    Lee TS; Chang CC; Zhu Y; Shyy JY
    Circulation; 2004 Sep; 110(10):1296-302. PubMed ID: 15337692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of statins on toll-like receptors: a new insight to pleiotropic effects.
    Bahrami A; Parsamanesh N; Atkin SL; Banach M; Sahebkar A
    Pharmacol Res; 2018 Sep; 135():230-238. PubMed ID: 30120976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulatory effects of HMG-CoA reductase inhibitors in diabetic microangiopathy.
    Danesh FR; Kanwar YS
    FASEB J; 2004 May; 18(7):805-15. PubMed ID: 15117885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New nonlipid effects of statins and their clinical relevance in cardiovascular disease.
    Undas A; Celińska-Löwenhoff M; Kaczor M; Musial J
    Thromb Haemost; 2004 Jun; 91(6):1065-77. PubMed ID: 15175791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arsenic modulates heme oxygenase-1, interleukin-6, and vascular endothelial growth factor expression in endothelial cells: roles of ROS, NF-κB, and MAPK pathways.
    Wang L; Kou MC; Weng CY; Hu LW; Wang YJ; Wu MJ
    Arch Toxicol; 2012 Jun; 86(6):879-96. PubMed ID: 22488045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?
    Schönbeck U; Libby P
    Circulation; 2004 Jun; 109(21 Suppl 1):II18-26. PubMed ID: 15173059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.